EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cyclin-dependent kinase 4/6 inhibitors combined with stereotactic ablative radiotherapy in oligometastatic HR-positive/HER2-negative breast cancer patients

Marcin Kubeczko iD, Dorota Gabryś, Aleksandra Krzywon, Michał Jarząb

British Journal of Radiology · 2024

DOI: 10.1093/bjr/tqae138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Radiology, 2024. Verfasst von Marcin Kubeczko und 3 weiteren Autor:innen. Beteiligte Einrichtung: Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, 44-102 Gliwice, Poland. Hauptthemen laut MEDLINE: Breast Neoplasms, Radiosurgery, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Maria Sklodowska-Curie National Research Institute of Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have significantly improved the survival of patients with hormone receptor-positive HER2-negative advanced breast cancer (ABC). Although stereotactic ablative radiotherapy (SABR) is used more often in routine clinical practice, data on the safety and efficacy of combining SABR with CDK4/6i are lacking. Herein, we present the results of SABR combined with CDK4/6i in ABC.

Methods

Patients with ABC who received CDK4/6i and SABR between 2018 and 2023 were analysed.

Results

Among 384 patients treated with CDK4/6i, 34 patients received 44 courses of SABR. Two-year progression-free survival (PFS) was 63.6% (95% CI, 45.8-88.3), and the median PFS was 32 months. Three-year overall survival (OS) was 88.9% (95% CI, 77.7-100). Two-year local control (LC) was 92.7% (95% CI, 83.4-100). Median OS and LC were not reached. The subgroup analysis showed the difference in survival between oligometastatic patients (OMD) and non-OMD subgroup. Two-year PFS was 69.2% (95% CI, 44.5-100) in OMD compared with 57.4% (95% CI, 36-91.7) in the non-OMD (P = .042). Three-year OS was 90% (95% CI, 73.2-100) in OMD compared with 86.2% (95% CI, 70-100) in the non-OMD (P = .67). Median PFS and OS in the non-OMD were 26 and 56 months, respectively, and were not reached in OMD. Fifteen patients required CDK4/6i dose reduction, and 2 discontinued treatment due to toxicity. No difference in high-grade toxicity was observed between the sequential and concurrent SABR.

Conclusion

The addition of SABR to CDK4/6i seems to be safe and effective, especially in patients with oligometastatic disease. Advances in knowledge In advanced breast cancer patients treated with CDK4/6i, SABR provides a high local control and may provide additional benefit in an oligometastatic setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsRadiosurgeryCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6HumansFemaleMiddle AgedAgedAdultAged, 80 and overErb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsCombined Modality TherapyRetrospective StudiesProgression-Free SurvivalNeoplasm Metastasis

Stichwörter der Autor:innen

cyclin-dependent kinase 4/6 inhibitorsoligometastatic diseasestereotactic ablative radiotherapy

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Erb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsCDK4 protein, humanCDK6 protein, humanERBB2 protein, human

Autor:innen und Institutionen

  • Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, 44-102 Gliwice, Poland.
  • Department of Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, 44-102 Gliwice, Poland.
  • Department of Biostatistics and Bioinformatics, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, 44-102 Gliwice, Poland.

ORCID-Profile: Marcin Kubeczko

Förderung

  • Maria Sklodowska-Curie National Research Institute of Oncology

Zitieren

APA

Kubeczko, M., Gabryś, D., Krzywon, A., & Jarząb, M. (2024). Cyclin-dependent kinase 4/6 inhibitors combined with stereotactic ablative radiotherapy in oligometastatic HR-positive/HER2-negative breast cancer patients. British Journal of Radiology. https://doi.org/10.1093/bjr/tqae138

Vancouver

Kubeczko M, Gabryś D, Krzywon A, Jarząb M. Cyclin-dependent kinase 4/6 inhibitors combined with stereotactic ablative radiotherapy in oligometastatic HR-positive/HER2-negative breast cancer patients. British Journal of Radiology. 2024. doi:10.1093/bjr/tqae138

BibTeX
@article{Kubeczko2024,
  author = {Kubeczko, Marcin and Gabryś, Dorota and Krzywon, Aleksandra and Jarząb, Michał},
  title = {Cyclin-dependent kinase 4/6 inhibitors combined with stereotactic ablative radiotherapy in oligometastatic HR-positive/HER2-negative breast cancer patients},
  journal = {British Journal of Radiology},
  year = {2024},
  doi = {10.1093/bjr/tqae138}
}
Kostenlos starten →